Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk Vertex Pharmaceuticals Incorporated (VRTX) is currently at $464.17, up $25.77 or 5.88% --Would ...

Physics Formulas for CBSE Class 10 Students: One of the subjects that students fears the most is Physics. The reason is formulas and derivations. What if you get the list of formulas together and ...

As you prepare for JEE 2025, revising important formulas is crucial to performing well in the exam. The JEE syllabus covers a vast array of topics in Physics, Chemistry, and Mathematics ...

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

Now that Extreme E is on a hiatus while it turns into Extreme H, and World Rallycross has switched to a competition between EVs and combustion, Formula E is back to being the primary fully ...

US car company General Motors has set up a new engine company as it gears up for its prospective entry into Formula 1. GM has an agreement in principle to start in F1 in 2026 with a new team named ...

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...

Now, under the expanded partnership, Formula E will further enhance its capabilities through a range of initiatives, including: Supercharging performance with generative AI: Google Cloud's ...

Season 11 of the ABB FIA Formula E World Championship kicks off the 2025 motorsport calendar year with Round 2 in Mexico City, Mexico, on Saturday, January 11. After a thrilling season opener in São ...

Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...